French drug developer Pharnext to take rare approach to pricing

A privately held French drug developer is taking a rare approach to pricing its drug intended to treat a rare disease. Pharnext SAS, whose drug is the only treatment in a late-stage trial for treating a rare inherited disorder called Charcot-Marie-Tooth (CMT), sees potential to earn a healthy profit by selling the yet-to-be approved drug for as little as 20 percent of the prevailing cost of most rare-disease drugs. Drug pricing has become a contentious issue among drugmakers and lawmakers in the United States, with companies like Valeant Pharmaceuticals and Turing Pharmaceuticals facing a backlash for sharply hiking prices of older drugs they have bought cheaply.

Original post: 
French drug developer Pharnext to take rare approach to pricing